
INmune Bio Investor Relations Material
Latest events

Status Update
INmune Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from INmune Bio Inc
Access all reports
INmune Bio, Inc. is a clinical-stage immunotherapy company. The company focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease and non-alcoholic steatohepatitis. It has several development programs, including INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19
Key slides for INmune Bio Inc


Corporate Presentation
INmune Bio Inc


Corporate Presentation
INmune Bio Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
INMB
Country
🇺🇸 United States